Clinical Trial Update: Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial investigates using the iron chelator MEX-CD1 added to dialysate to remove labile iron in sepsis-associated acute kidney injury; it's in Phas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Sepsis

Drugs mentioned

• MEX-CD1

Snippet

Sponsor: Centre Hospitalier Universitaire de Nīmes | Conditions: Acute Kidney Injury, Sepsis | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING